Global Health Clinic
Close this search box.


Our contribution to the fight against COVID-19

The civilization is in the minds of health care crises! Unhealthy lifestyle habits as well as aging population have resulted in a dramatic increase of various health conditions becoming an ever-increasing burden to the health care system. This could not be more evident than the ill-prepared health care sector to cope with the pandemic of COVID 19.

Empowering people to self-care has never been more dominant and imperative.

Member of the Zepter Group, Bioptron AG is a well-established Swiss company specialized in the field of Medicine and Health care that has for the past 30 years provided safe, non- invasive and effective medical Hyperlight therapy to prevent and treat illnesses and improve lives.

Bioptron Hyperlight Therapy System is

  • CLINICALLY TESTED, PROVEN & CERTIFIED for a wide range of medical conditions


Bioptron Hyperlight therapy reinforces the immune system, increases the capacity to fight against disease and accelerates the recovery.

BIOPTRON Hyperlight therapy is a unique method of immunomodulation. It supports our body in case of immunodepression, for example, in a post-surgery period, in oncology patients or in the case of previous respiratory diseases – in the situations where the immune system is affected and unable to protect the organism adequately. Bioptron Hyperlight therapy has also successfully been used as a conjunctive therapy to effectively strengthen the immune system and support the fight against any disease.

COVID-19 provokes an immunosuppressive condition, worsening different pathologies that in other context would not carry bigger consequences. Faced with no available cure, the population is frantically embracing stricter hygiene routines and protecting themselves by staying isolated or by using masks.

The best protective measure is to strengthen the immune system that will help the body to effectively fight viruses and bacteria. This is especially important for frail population, with already existing chronic conditions which complicate their health and facilitate the onset of an infection by other viruses or bacteria, aggravating their medical condition.

Bioptron Hyperlight Therapy– clinically tested, proven and certified Swiss medical device – stimulates the production of specific cytokines (small molecules acting as messengers between immune cells) that activate the cellular immunity, increasing the anti-viral and the anti-bacterial defense of the human body. Bioptron Hyperlight Therapy also normalizes other blood indexes (leukocytes count, level of inflammatory markers and immunoglobulins) which contribute to maintaining a strong and efficient immune system. Only optimized defense will assure more effective and a successful fight against external pathogens!

In leukocytes and other cells, Bioptron Hyperlight Therapy models DNA synthesis to adapt the immune response to an antigenic stimulus. Some cellular mechanisms of immune cells are enhanced, like antibody production and phagocytic activity of monocytes and granulocytes (capacity to ingest and destroy particles, as viruses, bacteria or tumor cells).

The immune cells responsible to orchestrate a coordinated and effective anti-viral and anti-bacterial response are more active and structurally modified to give a precise defense.

Using Bioptron Hyperlight Therapy on the low back region, the frontal bone of the skull and/or the sternum for only 10 minutes a day, will reinforce the immune system, increasing its capacity to defend the whole organism against external pathogens.

Easy to use. Painless. Time-effective. Economical. No known side effects. Suitable for everybody.

Bioptron Hyperlight therapy reinforces the immune system, increases the capacity to fight against disease and accelerates the recovery. This scientific study proofs the beneficial use of Bioptron devices to resist to viral infections, and more specifically against the influenza virus. The reinforcement of the immune system allows the organism to decrease the capacity of the virus to infect and spread into the tissues, improving the survival rate and the recovery process.

Hemagglutinin and infectious titer in lungs and blood serum of animals infected by Influenza virus H1/N1

In an experimental setup, mice were infected with influenza virus H1N1 AP/R/8/34 (the virus of influenza flu) at different doses (lethal and sublethal) (refAnthology, 2002). Half of them were used as the control group (infected by the virus) and the other half after infection of the virus were treated with Bioptron twice a day during 11 days. The researchers measured the survival of the mice, the hemagglutinin levels (virus protein implicated in the fusion of viral particles with cells) and the infection titer in lungs and the blood serum of both groups of mice.

First conclusion of these studies is that 0% of mice infected with the lethal dose of virus survived, but in the mice infected with the same dose and treated with Bioptron the survival was 20%. The same effect was reported in mice with sublethal dose: without Bioptron the survival was 50% and with Bioptron the survival was 80%.

The scientists discovered that 14 days after infection, the lungs and the blood of animals not treated with Bioptron were very affected by the viral infection – with high levels of hemagglutinin and high infection rate, meaning a high viral propagation in mice tissues. On the contrary, mice treated with Bioptron showed 4 times less hemagglutinin levels in lungs and blood, and the infection rate was reduced in more than 20 times. Decreased levels of the virus show that its reproduction was suppressed under the influence of Bioptron Hyperlight Therapy. This result shows an increase in the survival index of tested animals. Mice treated with Bioptron were fighting better and controlling better the capacity of infection against the influenza virus.

In conclusion, treatment with Bioptron Hyperlight Therapy leads to the restoration of the protective activity of the blood. This impairs the reproduction of the virus and the viral infection of the cells, thus increasing the survival of animals.


  • Fenyö M, Mandl J, Falus A (2002) Opposite Effect of Linearly Polarized Light in Biosynthesis of Interleukin-6 in a Human b Lymphoid Cell Line and Peripheral Human Monocytes. Cell Biology International 2002; 26(3): pp 265-269
  • Kubasova T, Fenyö M, Somosy Z, Gazso L, Kertész I (1988) Investigations on biological effect of polarized light. Photochem and Photobiol 1988; 48(4): pp 505-509
  • Kubasova T, Horváth M, Kocsis K, Fenyö M (1995) Effect of visible light on some cellular and immune parameters. Immunology and Cell Biology 1995; 73: pp 239-244
  • Zhevago NA, Samoilova KA, Obolenskaya KD (2004) The regulartory effect of polychromatic (visible and infrared) light on human humoral immunity. Photochem. Photobiol. Sci. 2004: 3; pp 102- 108
  • Monteiro J, Aciole G, Cangusso MC, Santos J, Barbosa Pinheiro A (2009) Effects of visible or IR Laser light on the progression of chemo-induced oral dysplasia: In vivo study on the hamster cheek pouch model. Mechanisms for Low-Light Therapy IV 2009 February 18; p
  • Falus A, Fenjő M, Èder K,Madarasi A (2011) Genome-wide gene expression study indicates the anti-inflammatory effect of polarized light in recurrent childhood respiratory disease. Inflammation Research 2011: 60(10), pp 965-972
  • Zhevago NA, Samoila KA (2006) Pro- and anti-inflammatory cytokine content in human peripheral blood after its transcutaneous (in vivo) and direct (invitro) irradiation with polychromatic visible and infrared light. Photomed Laser Surg 2006 Apr; 24(2): pp 129-139
  • Bogacheva ON, Samoĭlova KA, Zhevago NA, Obolenskaia KD, Blinova MI, Kalmykova NV,
  • Kuz’minykh EV (2004) Enhancement of fibroblast growth promoting activity of human blood after its irradiation in vivo (transcutaneously) and in vitro with visible and infrared polarized light. Tsitologiia 2004; 46(2): pp 159-17

Global Health Clinics, 409 Lake Rd, Takapuna, Auckland 0622